相关实验视频

Updated: May 21, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

患有急性冠状动脉综合征的患者的大型非阻塞性冠状动脉血栓:可以保守治疗吗?

Iosif Xenogiannis¹, Loukianos S Rallidis¹, Ilias Bakirtzis¹

¹Second Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens, Chaidari, Athens, Greece.

JACC. Case reports

|March 21, 2025

概括

一名患有急性冠状动脉综合征和大冠状动脉血栓的年轻患者经历了保守的抗血栓治疗的完全康复. 这一案例凸显了冠状动脉血栓不发生斑块破裂的非侵入性治疗的潜力.

科学领域:

心脏病学心脏病学
干预心脏病学干预心脏病学
血栓形成的管理

背景情况:

年轻患者的急性冠状动脉综合征 (ACS) 通常与斑块破裂和血栓形成有关.
左前下垂冠状动脉血栓 (LAD) 构成心肌梗塞的重大风险.
冠状动脉栓塞的保守管理通常保留在特定的临床场景中.

研究的目的:

报告一个成功保守管理大LAD血栓的病例,该病例发生在患有ACS的年轻患者身上.
评估强化抗血栓治疗在治疗冠状动脉瘤中的有效性.
评估光学连贯断层扫描 (OCT) 在指导冠状动脉血栓的管理决策中的作用.

主要方法:

一个年轻患者的病例报告呈现了ACS和LAD血栓.
最初的保守治疗与强烈的抗血栓治疗.
序列冠状动脉血管学和光学连贯性断层扫描 (OCT) 进行血栓评估.

主要成果:

在LAD中的大血栓最初被保守地用抗血栓治疗治疗.
在2天后重复血管造影显示持续的血栓,但在治疗7天后观察到解决.
光学连贯断层扫描没有发现斑块破裂的证据,支持了保守的方法,避免了血管造形手术的需要.

结论:

密集的抗血栓治疗可以导致大冠状动脉瘤在选择的ACS的年轻患者中完全消失.
海洋和海洋是识别斑块破裂的缺失的宝贵工具,指导保守的管理策略.
在没有斑块破裂和持续的缺血的情况下,保守的治疗可能是冠状动脉瘤血管整形术的可行替代方案.

关键词:

其他IIb/IIIa抑制剂.急性冠状动脉综合征急性冠状动脉综合征光学连贯性断层扫描技术血栓形成的原因是因为血栓.

更多相关视频

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...